Whole Genome Sequencing Better at Tracing TB Outbreaks
|
By LabMedica International staff writers Posted on 25 Feb 2013 |
A study revealed that a new form of genetic testing of the bacteria that cause tuberculosis (TB) provides better information on TB transmission and thus allows tracing of TB outbreaks more accurately than the current standard tests.
A team of experts from public-health institutions, research institutes, and universities in Germany and France led by Stefan Niemann from the Forschungszentrum Borstel (Borstel, Germany) compared the results of the two types of tests on 86 Mycobacterium tuberculosis isolates from a TB outbreak in the German states Hamburg and Schleswig-Holstein (overall 2301 TB cases have been investigated in the study period from 1997 to 2010).
They found that the new test, based on the sequencing of the respective whole genomes (i.e., whole genome sequencing, WGS) provided more accurate information on clustering and temporal spread of the pathogen than the standard tests, which are based on the analysis of small genome regions (classical genotyping). Importantly, while standard tests were not able to distinguish the strains involved, WGS-based analyses revealed that only a particular clone started spreading at the onset of the outbreak, suggesting that subtle differences in the genome might influence the success of pathogen transmission.
"Only genome based investigations allowed us to trace the spread of M. tuberculosis with the resolution needed to visualize transmission patterns correctly," said Dr. Andreas Rötzer, first author of the study.
Genotyping of M. tuberculosis strains is usually used to detect TB outbreaks and guide tracing contacts of TB cases. However, standard genotyping analyses only tiny parts of the genome, and may therefore not be able to distinguish between closely related strains spreading in distinct transmission chains. This was confirmed by this study: WGS-based typing discriminated better the different strain variants involved in the outbreak, was in better agreement with information on known contacts between the patients, and allowed the investigators to more precisely follow the spread of clones over space and time.
Based on the genome sequencing data, the authors were also able to estimate that the genome of M. tuberculosis evolves in its natural host population (infected individuals) at a slower mutation rate than other bacterial pathogens (0.4 mutations per genome per year). This measure of the bacterium’s mutation rate will be useful to trace future outbreaks and estimate when and via which individual they originated.
An additional advantage of WGS compared to standard genotyping is that WGS allows the identification of mutations of bacterial genes causing antibiotic resistance mutations and variations in virulence genes. This is especially important as M. tuberculosis strains that are resistant to the most potent drugs are increasingly emerging in several world regions and rapid detection of resistance is crucial for successful treatment.
The costs of whole genome analysis based on Next Generation Sequencing are declining; therefore, this test could soon become the standard method for identifying transmission patterns and rates of infectious disease outbreaks.
In addition, the authors state: “We envision that the progressive effective implementation of WGS for Public Health and medical diagnostics will also be accelerated by the broader distribution of more accessible and flexible sequencing machines, and upcoming bioinformatics developments to facilitate quick and relevant interpretation of the resulting data by the clinical and medical staff.”
The study was published in PLOS Medicine on February 12, 2013.
Related Links:
Forschungszentrum Borstel
A team of experts from public-health institutions, research institutes, and universities in Germany and France led by Stefan Niemann from the Forschungszentrum Borstel (Borstel, Germany) compared the results of the two types of tests on 86 Mycobacterium tuberculosis isolates from a TB outbreak in the German states Hamburg and Schleswig-Holstein (overall 2301 TB cases have been investigated in the study period from 1997 to 2010).
They found that the new test, based on the sequencing of the respective whole genomes (i.e., whole genome sequencing, WGS) provided more accurate information on clustering and temporal spread of the pathogen than the standard tests, which are based on the analysis of small genome regions (classical genotyping). Importantly, while standard tests were not able to distinguish the strains involved, WGS-based analyses revealed that only a particular clone started spreading at the onset of the outbreak, suggesting that subtle differences in the genome might influence the success of pathogen transmission.
"Only genome based investigations allowed us to trace the spread of M. tuberculosis with the resolution needed to visualize transmission patterns correctly," said Dr. Andreas Rötzer, first author of the study.
Genotyping of M. tuberculosis strains is usually used to detect TB outbreaks and guide tracing contacts of TB cases. However, standard genotyping analyses only tiny parts of the genome, and may therefore not be able to distinguish between closely related strains spreading in distinct transmission chains. This was confirmed by this study: WGS-based typing discriminated better the different strain variants involved in the outbreak, was in better agreement with information on known contacts between the patients, and allowed the investigators to more precisely follow the spread of clones over space and time.
Based on the genome sequencing data, the authors were also able to estimate that the genome of M. tuberculosis evolves in its natural host population (infected individuals) at a slower mutation rate than other bacterial pathogens (0.4 mutations per genome per year). This measure of the bacterium’s mutation rate will be useful to trace future outbreaks and estimate when and via which individual they originated.
An additional advantage of WGS compared to standard genotyping is that WGS allows the identification of mutations of bacterial genes causing antibiotic resistance mutations and variations in virulence genes. This is especially important as M. tuberculosis strains that are resistant to the most potent drugs are increasingly emerging in several world regions and rapid detection of resistance is crucial for successful treatment.
The costs of whole genome analysis based on Next Generation Sequencing are declining; therefore, this test could soon become the standard method for identifying transmission patterns and rates of infectious disease outbreaks.
In addition, the authors state: “We envision that the progressive effective implementation of WGS for Public Health and medical diagnostics will also be accelerated by the broader distribution of more accessible and flexible sequencing machines, and upcoming bioinformatics developments to facilitate quick and relevant interpretation of the resulting data by the clinical and medical staff.”
The study was published in PLOS Medicine on February 12, 2013.
Related Links:
Forschungszentrum Borstel
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







